{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:33Z","timestamp":1793957193246,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107949","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:38:36Z","timestamp":1790404716000},"page":"107949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relapse and disability across the disease course of MOGAD: a real-world cohort study from northern China"],"prefix":"10.1016","volume":"115","author":[{"given":"Peihang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-3419","authenticated-orcid":false,"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107949_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107949_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105950","article-title":"Clinical characteristics of pediatric and adult myelin oligodendrocyte antibody-associated disease (MOGAD): a single-center study in the Northeast","volume":"92","author":"Brown","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107949_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200547","article-title":"Validation of the MOG-AR score: a retrospective multicenter study","volume":"13","author":"Carta","year":"2026","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107949_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107949_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107949_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000211822","article-title":"Clinical features and factors associated with outcome in late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"104","author":"Dinoto","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107949_bib0007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jnnp-2024-334613","article-title":"Fewer relapses and worse outcomes of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Fan","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107949_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10522-015-9578-8","article-title":"Inflammaging decreases adaptive and innate immune responses in mice and humans","volume":"17","author":"Frasca","year":"2016","journal-title":"Biogerontology"},{"key":"10.1016\/j.msard.2026.107949_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107949_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578709","article-title":"Prolonged corticosteroid therapy and steroid-sparing maintenance immunotherapy lower relapse risk in pediatric and adult MOGAD","volume":"407","author":"Hoshina","year":"2025","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107949_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2026.107949_bib0012","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107949_bib0013","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1177\/13524585251320046","article-title":"Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"31","author":"Kang","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107949_bib0014","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107949_bib0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107949_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105093","article-title":"Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis","volume":"80","author":"Molazadeh","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107949_bib0017","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1352458518811597","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"25","author":"Oliveira","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107949_bib0018","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107949_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105672","article-title":"Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"87","author":"Rempe","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107949_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.stem.2011.11.019","article-title":"Rejuvenation of regeneration in the aging central nervous system","volume":"10","author":"Ruckh","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.msard.2026.107949_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2026.107949_bib0022","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nn.2172","article-title":"Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency","volume":"11","author":"Shen","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.msard.2026.107949_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1234572","article-title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration","volume":"4","author":"Thakolwiboon","year":"2023","journal-title":"Front. Aging"},{"key":"10.1016\/j.msard.2026.107949_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106631","article-title":"Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset","volume":"102","author":"Tisavipat","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107949_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2026.107949_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107949_bib0027","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jnnp-2024-333464","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Virupakshaiah","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107949_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107949_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200309","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107949_bib0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00415-026-13754-9","article-title":"Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score","volume":"273","author":"Yeh","year":"2026","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:38:03Z","timestamp":1793954283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"alternative-id":["S2211034826009843"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107949","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse and disability across the disease course of MOGAD: a real-world cohort study from northern China","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107949"}}